[go: up one dir, main page]

WO2009015840A3 - Polypeptide for targeting of neural cells - Google Patents

Polypeptide for targeting of neural cells Download PDF

Info

Publication number
WO2009015840A3
WO2009015840A3 PCT/EP2008/006151 EP2008006151W WO2009015840A3 WO 2009015840 A3 WO2009015840 A3 WO 2009015840A3 EP 2008006151 W EP2008006151 W EP 2008006151W WO 2009015840 A3 WO2009015840 A3 WO 2009015840A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
neural cells
targeting
increased
decreased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/006151
Other languages
French (fr)
Other versions
WO2009015840A2 (en
Inventor
Tanja Weil
Andreas Rummel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of WO2009015840A2 publication Critical patent/WO2009015840A2/en
Publication of WO2009015840A3 publication Critical patent/WO2009015840A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides a polypeptide having an increased or decreased affinity with respect to its receptor on neural cells, an increased or decreased neurotoxicity and/or a reduced affinity for neutralising antibodies against botulinum neurotoxin A. Further, active fragments or derivatives are provided. In addition, pharmaceutical and cosmetic uses thereof are indicated. Also, methods for producing and using them are disclosed.
PCT/EP2008/006151 2007-07-27 2008-07-25 Polypeptide for targeting of neural cells Ceased WO2009015840A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95233507P 2007-07-27 2007-07-27
EP07014785 2007-07-27
US60/952,335 2007-07-27
EP07014785.5 2007-07-27

Publications (2)

Publication Number Publication Date
WO2009015840A2 WO2009015840A2 (en) 2009-02-05
WO2009015840A3 true WO2009015840A3 (en) 2009-07-09

Family

ID=40011272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/006151 Ceased WO2009015840A2 (en) 2007-07-27 2008-07-25 Polypeptide for targeting of neural cells

Country Status (1)

Country Link
WO (1) WO2009015840A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009286973B2 (en) 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
JP5990176B2 (en) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン Mammalian excipient-free preparation suitable for protein stabilization
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP2952205B1 (en) 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
TWI669129B (en) 2014-12-23 2019-08-21 德商梅茲製藥有限兩合公司 Refilled glass container, a kit comprising the same and, a use thereof
US11268080B2 (en) * 2015-03-26 2022-03-08 President And Fellows Of Harvard College Engineered botulinum neurotoxin
TWI737742B (en) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 Botulinum toxin prefilled syringe system, kit having the same and use thereof
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
GB202103372D0 (en) * 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027207A1 (en) * 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006078567A2 (en) * 2005-01-21 2006-07-27 Montana State University Vaccines and mucosal targeting ligands to facilitate vaccine delivery
WO2006114308A2 (en) * 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027207A1 (en) * 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006078567A2 (en) * 2005-01-21 2006-07-27 Montana State University Vaccines and mucosal targeting ligands to facilitate vaccine delivery
WO2006114308A2 (en) * 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 28 March 2005 (2005-03-28), "Clostridium botulinum strain FRI-H1A2 type A2 botulinum neurotoxin gene, complete cds.", XP002505754, retrieved from EBI accession no. EMBL:AY953275 Database accession no. AY953275 *
RUMMEL A ET AL: "The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction", MOLECULAR MICROBIOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 51, no. 3, 15 December 2003 (2003-12-15), pages 631 - 643, XP002363868, ISSN: 0950-382X *
SMITH T J ET AL: "Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 73, no. 9, 1 September 2005 (2005-09-01), pages 5450 - 5457, XP002392366, ISSN: 0019-9567 *
WILLEMS A ET AL: "Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins", RESEARCH IN MICROBIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 7, 1 January 1993 (1993-01-01), pages 547 - 556, XP023924679, ISSN: 0923-2508, [retrieved on 19930101] *

Also Published As

Publication number Publication date
WO2009015840A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
WO2009015840A3 (en) Polypeptide for targeting of neural cells
WO2006114308A3 (en) Carrier for targeting nerve cells
WO2009009523A3 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2009142460A3 (en) Antibody-peptide fused synergibody
WO2007117505A3 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2008079973A9 (en) EGF RECEPTOR BINDING PEPTIDES AND USES THEREOF
WO2008054858A3 (en) Anionic fuel cells, hybrid fuel cells, and methods of fabrication thereof
WO2009058957A3 (en) Intranasal administration of active agents to the central nervous system
WO2008106646A3 (en) Methods and formulations for topical gene therapy
WO2009114093A3 (en) Methods for transforming yeast
WO2006129085A3 (en) High affinity melan-a t cell receptors
WO2011056954A3 (en) Haemophilus parasuis polypeptides and methods of use
WO2010014922A3 (en) Protein purification tags and uses thereof
WO2008110374A3 (en) Pellets containing a pharmaceutical substance, method for the production thereof and use of the same
WO2008054595A3 (en) Drug controlled molecular tags
WO2008089339A3 (en) Oligosaccharide conjugates for cellular targeting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785104

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08785104

Country of ref document: EP

Kind code of ref document: A2